Pacira BioSciences (PCRX) Share-based Compensation (2010 - 2026)

Pacira BioSciences' Share-based Compensation history runs 17 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 70.07% year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $47.3 million, a 2398.89% increase from a year earlier, with the FY2025 full-year figure at $57.5 million, up 11611.2% from the prior year.
• Share-based Compensation eased to $4.4 million in Q1 2026 per PCRX's latest filing, from $13.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $15.5 million in Q2 2025 and bottomed at -$38.4 million in Q4 2024.
• The 5-year median for Share-based Compensation is $12.5 million (2024), against an average of $6.5 million.
• Across the five-year window, Share-based Compensation tumbled 409.29% in 2024 and jumped 135.14% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at -$35.4 million in 2022, then surged by 135.07% to $12.4 million in 2023, then tumbled by 409.29% to -$38.4 million in 2024, then soared by 135.14% to $13.5 million in 2025, then plunged by 67.74% to $4.4 million in 2026.
• Per Business Quant, the three latest PCRX Share-based Compensation figures stand at $4.4 million (Q1 2026), $13.5 million (Q4 2025), and $14.0 million (Q3 2025).